Real-Life Therapeutic Concentration Monitoring of Long-Acting Cabotegravir and Rilpivirine: Preliminary Results of an Ongoing Prospective Observational Study in Switzerland
, Susana Alves Saldanha 1, Fabian Schaller 1, Aline Munting 2, Matthias Cavassini 2, Dominique Braun 3,4, Huldrych F. Günthard 3,4, Katharina Kusejko 3,4, Bernard Surial 5, Hansjakob Furrer 5, Andri Rauch 5, Pilar Ustero 6, Alexandra Calmy 6,7, Marcel Stoeckle 8, Manuel Battegay 8,9, Catia Marzolini 8,9,10, Pascal Andre 1, Monia Guidi 1,11,12, Thierry Buclin 1, Laurent A. Decosterd 1,* and add
Show full author list
Round 1
Reviewer 1 Report
The work is significant and effectively addresses the problems raised in the title. I believe it will be beneficial if it is published and distributed to the scientific community. In fact, the text needed considerable grammar and English language correction. I submitted the paper for plagiarism detection, and I am accepting it with minimal changes in the hopes that it will not be rejected.
Author Response
We thank the reviewer for the positive global appreciation of our article and our study.
We have checked English language and style. We hope that the reviewer will find the revised version suitable for publication.
Reviewer 2 Report
The present study by Thoueille et al is highly significant. With long-acting ART (LA-ART) therapy, we anticipate many more such kinds of studies. Moreover, for the success of LA-ART therapy continuously performing this kind of analysis are highly crucial and essential.
Comments for author File: 
Comments.pdf
Author Response
We thank the reviewer for the very favorable appreciation of our article and enthusiastic comments towards our study.
The English language and style have been checked.
Reviewer 3 Report
The study brings important info on real-life data of long-acting cabotegravir and rilpivirine.
Author Response
We certainly acknowledge that the article may be improved.
As stated in the article, this is an ongoing study, and a substantial number of additional patients and new PK data has been available since the time of article submission: we went from 15 patients with 39 samples collected, to 46 patients with 91 samples collected. These additional data have been incorporated into the updated analyses. The consolidated results strengthen our preliminary observations on the long-acting cabotegravir and rilpivirine in a real-life cohort of people living with HIV
According to the recommendations, the English language and style have been checked.
